Life Sciences

  • July 27, 2026

    Albertsons Opioid Trial Told Of Needles, ODs In Library

    A witness in Washington's case accusing Albertsons Cos. Inc. of fueling the state's opioid crisis testified at a bench trial Monday that problem drug use was evident in a city library system she's led for nearly a decade, pointing to syringes scattered across the facility and multiple instances of overdoses.

  • July 27, 2026

    J&J, Ovarian Cancer Talc Claimants Unveil $5.5B Global Deal

    Johnson & Johnson announced Monday that it has agreed to pay some $5.5 billion to put to rest tens of thousands of lawsuits alleging its talcum powder products caused ovarian cancer, with plaintiffs' counsel calling the deal "long-delayed justice" for their clients.

  • July 27, 2026

    Union Funds Seek Final OK For $180M In Opioid Deals

    Union health and welfare funds have asked the Ohio federal judge overseeing the sprawling national opioid litigation to approve settlements totaling $180 million with CVS, Walgreens, Walmart and three pharmaceutical companies to compensate for the costs of opioid use disorder treatment.

  • July 27, 2026

    Taco Bell, Taylor Farms Hit With Another Cyclospora Suit

    Consumers have filed another suit in Michigan federal court against Taco Bell and produce supplier Taylor Farms, alleging that the companies' negligence caused them to suffer cyclospora infections after eating contaminated iceberg lettuce sold at Taco Bell restaurants.

  • July 27, 2026

    Fed. Circ. Clears Boston Scientific In $49M Stent Patent Case

    The Federal Circuit on Monday overturned a $49.4 million patent judgment against Boston Scientific, ruling that the company's drug-eluting coronary stents did not infringe a patent owned by the University of Texas System and that the patent is invalid.

  • July 27, 2026

    Hygiene Co. Can't Fight FTC's Need To Back Up COVID Claims

    Xylitol-based hygiene products company Xlear can't challenge the Federal Trade Commission's general insistence that companies "substantiate" health claims like COVID-19 protections, because the FTC isn't currently suing over those claims, a Utah federal judge ruled Monday.

  • July 27, 2026

    Cooley Owes $25.4M Judgment To NJ Biotech Co. Founder

    A New Jersey state court on Monday entered a $25.4 million judgment against Cooley LLP after a jury found the multinational firm had committed malpractice in its representation of a biotech founder who said his own lawyers assisted in shoving him out of his company.

  • July 27, 2026

    Verano Unit Accused Of Infringing Cannabis Extraction Patent

    A subsidiary of cannabis giant Verano Holdings LLC was hit with a patent infringement suit in Virginia federal court Monday accusing it of ripping off a California company's pioneering technology using safer, low-temperature ethanol extraction processes to obtain oils and compounds from cannabis, which helps avoid the risk of fires or explosions. 

  • July 27, 2026

    Quinn Emanuel's Ethics Training 'Promising,' Judge Says

    A California federal judge Monday approved a court-ordered ethics training program prepared by Quinn Emanuel in the wake of misrepresentations the firm made concerning an expert in a false advertising suit brought by Guardant Health against its client Natera, saying the firm had designed an "extremely promising" eight-hour program.

  • July 27, 2026

    Health Data Co. Inks $4.8M Settlement To End Investor Suit

    The health diagnostics company formerly known as Sema4 has reached a $4.8 million settlement with investors accusing the company of misleading them about a nonexistent, artificial intelligence-driven data platform it claimed to operate.

  • July 27, 2026

    Yale, Biohaven Win $4M In Biotech Trade Secret Trial

    A Delaware federal jury has awarded Yale University and Biohaven Therapeutics $4 million after finding that venture capital firm RA Capital Management GP breached a confidentiality agreement and, along with co-defendant Avilar Therapeutics, misappropriated a Yale-developed trade secret for designing protein-degrading drug molecules.

  • July 27, 2026

    AbbVie Seeks Block On Alkem Generic Constipation Drug

    AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic-drug maker Alkem Laboratories from selling generic versions of their branded constipation drug while associated patents are active, arguing Alkem would violate patent law by doing so.

  • July 27, 2026

    Regeneron Says Drug Approval Irrelevant In Antitrust Case

    Regeneron told a Delaware federal court the recent regulatory approval of a new cholesterol drug is irrelevant to its case accusing Amgen of bundling Repatha with other medications, as the court mulls an injunction bid following Regeneron's $407 million jury win.

  • July 27, 2026

    Hemp Co. Says DEA Defied Farm Bill By Banning HHC

    A North Carolina hemp company challenging the legality of a recent U.S. Drug Enforcement Administration rule designating a psychoactive hemp-derived compound as a Schedule I substance has told the Fourth Circuit that the agency defied Congress when it issued the rule.

  • July 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving restrictive covenants, corporate governance, trade secrets, real estate investments, receiverships, and books and records demands.

  • July 27, 2026

    Stewart Leaving USPTO This Week For Private Sector Job

    Deputy U.S. Patent and Trademark Office Director Coke Morgan Stewart will leave the office this week to return to the private sector, she told the USPTO executive staff Monday in a message obtained by Law360.

  • July 27, 2026

    Cannabis In The Courts: A Midyear Litigation Review

    In the first half of 2026, lawsuits taking aim at recent federal shifts in cannabis policy, a federal ban on marijuana users owning firearms and purported residency criteria in state cannabis licensure programs were argued in multiple courts across the country.

  • July 27, 2026

    Alkegen Files Ch. 11 In Texas To Shed $3.1B In Debt

    Alkegen and dozens of affiliates filed a prepackaged Chapter 11 case in Texas bankruptcy court, where the specialty materials maker intends to cut the bulk of its $3.3 billion of funded debt obligations.

  • July 27, 2026

    Arnold & Porter Hires King & Spalding ITC-Focused Atty

    Arnold & Porter Kaye Scholer LLP has hired a King & Spalding LLP partner in Washington, D.C., who will continue his intellectual property work focused on the cross-border aspects of technology and life sciences disputes, the firm announced Monday.

  • July 27, 2026

    Commerce Orders Duties On Korean Chemical Imports

    Certain monomers and oligomers imported into the U.S. from South Korea will be tagged with antidumping duties following an order by the U.S. Department of Commerce on Monday.

  • July 24, 2026

    Abbott Beats 'Supersized' Investor Suit Over Formula Recall

    An Illinois federal judge tossed a proposed securities class action accusing Abbott Laboratories of misleading shareholders about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, saying Friday that "despite its girth," the "supersized" complaint says "too much and too little," and still needs more information to be viable.

  • July 24, 2026

    Abbott Wins 7th Circ. Fight Over Baby Formula Warning

    The Seventh Circuit on Friday refused to revive a woman's claims that Abbott Laboratories failed to warn about the dangers of a Similac-brand infant formula her baby drank before dying of a serious gastrointestinal disease, saying she failed to show that her suggested alternative warning would have saved her baby.

  • July 24, 2026

    Va. Court Orders FDA To Reconsider Mifepristone Restrictions

    A Virginia federal judge held that a 2023 regulation by the U.S. Food and Drug Administration unlawfully placed prescribing restrictions on the abortion drug mifepristone, agreeing with a group of abortion providers that the agency inadequately addressed burdens on the healthcare system.

  • July 24, 2026

    Insulin Pen Lawsuit Against Novo Nordisk Headed For Trial

    A Connecticut federal judge refused on Friday to give Griffin Health Services Corp. a loss in its lawsuit over allegedly inadequate warnings on Novo Nordisk insulin pens, finding the hospital raised triable questions about whether the company failed to alert nurses to contamination risks and criticizing Novo for filing multiple summary judgment motions.

  • July 24, 2026

    9th Circ. Revives Ex-Kaiser Worker's Vaccine Bias Suit

    A Ninth Circuit panel Friday revived a former Kaiser Permanente employee's discrimination suit accusing The Permanente Medical Group Inc. of unlawfully firing her for refusing a mandatory COVID-19 vaccine, ruling that the worker adequately informed the company of the vaccine's conflict with her sincerely held religious beliefs.

Expert Analysis

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

  • High Court 'Skinny Label' Case Will Matter To Tech Litigators

    Author Photo

    Hikma v. Amarin, set for oral argument in the U.S. Supreme Court on Wednesday, has potential to affect not just generic drug label-based evidence in patent cases, but also how technology inducement cases are presented and proven, says attorney Abdul Abdullahi.

  • How Food, Beverage Claims May Preview Cosmetic Litigation

    Author Photo

    Class action litigation targeting cosmetics and personal care products is accelerating, with a playbook that comes from the food and beverage industry — and the defenses that succeeded, and failed, in past class actions offer a critical road map for beauty and personal care brands, say attorneys at Crowell.

  • Court's HRSA Policy Reversal Leaves 340B Rules Murky

    Author Photo

    A D.C. federal court's recent decision in Premier v. U.S. Department of Health limits the Health Resources and Services Administration's ability to enforce long-standing Section 340B interpretations through subregulatory guidance, leaving open core statutory questions about purchasing models, inventory classification and program oversight, says Martha Cramer at Hooper Lundy.

  • Series

    Officiating Football Makes Me A Better Lawyer

    Author Photo

    Though they may seem to have little in common, officiating football has sharpened many of the same skills that define effective lawyering in management-side labor and employment: preparation, judgment, composure, credibility and ability to make difficult decisions in real time, says Josh Nadreau at Fisher Phillips.

  • Fresenius Ruling May Shift Anti-Kickback Enforcement

    Author Photo

    The Ninth Circuit's recent decision in Fresenius v. Bonta suggests that businesses have a First Amendment right to donate to certain charities, even if those donations are motivated by economic self-interest, potentially calling into question years of Anti-Kickback Statute proceedings against pharmaceutical manufacturers for making similar donations, says Jonah Knobler at Patterson Belknap.

  • Written Consent Ruling May Signal Change For Telemarketing

    Author Photo

    The Fifth Circuit's ruling in Bradford v. Sovereign Pest Control is a takedown of the Federal Communications Commission's prior express written consent regulation, and because Loper Bright empowers courts to disregard agency interpretations, Telephone Consumer Protection Act litigants now have an opportunity to challenge previously settled FCC regulations, orders and interpretations, say attorneys at Manatt.

  • Series

    Law School's Missed Lessons: How To Draft Pleadings

    Author Photo

    Most law school graduates step into their first jobs without ever having drafted a complaint, answer, motion or other type of pleading, but that gap can be closed by understanding the strategy embedded in every filing, writing with clarity and purpose, and seeking feedback at every step, says Eric Yakaitis at Haug Barron.

  • At The Fed. Circ., Means-Plus-Function Is Not Quite Dead

    Author Photo

    Recent Federal Circuit opinions confirm that means-plus-function claims continue to be drafted, issued, litigated and even infringed — but minding the restrictions imposed over the years by courts and statute requires three steps, says Jay Yates at Patterson & Sheridan.

  • E-Discovery Quarterly: Recent Rulings On ESI Control

    Author Photo

    Several recent federal court decisions have perpetuated a split over what constitutes “control” of electronically stored information — with judges divided on whether the standard should turn on a party's legal right or practical ability to obtain the information, say attorneys at Sidley.

  • Opinion

    USPTO Should Let Inventors Valuate Patents In Prosecution

    Author Photo

    By building patent valuation into the application process, rather than waiting until potential litigation years down the line, the U.S. Patent and Trademark Office would streamline the process for inventors protecting and enforcing their patents, says John Powers at Powers IP.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.